Help us take the next step in the climb to treat pediatric cardiomyopathy
Purpose of the MyClimb Study
MyClimb seeks to collect and evaluate patient medical information, family history and other related information for use in medical research and drug development by researchers, including the study sponsor, Tenaya Therapeutics, and its partners, contractors and agents.
For the purpose of this study, “patient” refers to the person with a known MYBPC3 genetic mutation. As used throughout, “you” refers to a minor patient as well as the person providing the information, who may be the patient, a family member or guardian who is legally responsible for the care and health of the patient, or is authorized to share such information as part of the study.
During the five-year study, researchers will gather data to help characterize and evaluate the natural history of the disease course, burden of illness, risk factors and biomarkers associated with disease progression. This study is conducted under the independent oversight of an Institutional Review Board. There is no cost to participate in this study.
Study assessments are designed to be conducted during planned office visits. Aside from an annual blood draw, all assessments are non-invasive.